Thurston Springer Miller Herd & Titak’s Viking Therapeutics VKTX Stock Holding History

Thurston Springer Miller Herd & Titak’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-3,500	Closed	-$92.8K	–	1334
2025 Q2	$92.8K	Hold	3,500	–	–	0.01%	523
2025 Q1	$84.5K	Hold	3,500	–	–	0.01%	496
2024 Q4	$141K	Buy	3,500 +3,000	+600%	+$171K	0.03%	326
2024 Q3	$31.7K	Hold	500	–	–	0.01%	684
2024 Q2	$26.5K	Buy	+500	New	+$32.8K	0.01%	724

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Thurston Springer Miller Herd & Titak's VKTX Position: Q3 2025 in Review

Thurston Springer Miller Herd & Titak sold out of Viking Therapeutics (VKTX) in Q3 2025, closing a stake of 3,500 shares — an estimated $92.8K sold.

Thurston Springer Miller Herd & Titak first reported a position in VKTX in Q2 2024 and held it in 5 quarters. The position peaked at $141K in Q4 2024. 370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

Thurston Springer Miller Herd & Titak reported no remaining Viking Therapeutics position as of Q3 2025 after selling out during the quarter.
Thurston Springer Miller Herd & Titak sold 3,500 Viking Therapeutics shares in Q3 2025, an estimated $92.8K.
Thurston Springer Miller Herd & Titak first reported a position in Viking Therapeutics in Q2 2024 and held it in 5 quarters.
Thurston Springer Miller Herd & Titak's Viking Therapeutics position peaked at $141K in Q4 2024.
370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Thurston Springer Miller Herd & Titak's 13F filing for Q3 2025, filed 7 Oct 2025.